Opportunity Information: Apply for PA 25 163
The National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health (NIH), is inviting applications for a discretionary grant opportunity titled "Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)" (Funding Opportunity Number PA 25 163). This program uses the R01 mechanism and specifically requires clinical trials, meaning proposed projects are expected to involve human participants and test interventions or strategies in a controlled, structured way. The overall goal is to advance research that improves treatment and supports recovery for people with alcohol use disorder (AUD), with an emphasis on practical, evidence-driven approaches that can make a real difference in clinical care and long-term outcomes.
The scope is intentionally broad across the AUD treatment and recovery continuum. NIAAA is seeking studies that address treatment development and optimization, including medications development (pharmacotherapy) and other biological or combined approaches. The announcement also highlights precision medicine, pointing to interest in tailoring treatment based on individual differences such as biology, clinical presentation, co-occurring conditions, patterns of alcohol use, or other measurable factors that may predict which treatments work best for which people. Alongside medication-focused work, the opportunity strongly supports behavioral therapies and research on mechanisms of behavioral change (MOBC), which typically involves identifying and testing the key processes through which behavioral interventions produce improvements (for example, changes in coping skills, craving regulation, decision-making, stress response, social support, or other mediators of change).
In addition to treatment itself, the NOFO emphasizes recovery research, which can include topics like sustaining remission, preventing relapse, improving functioning and quality of life, and understanding recovery trajectories over time. It also calls out translational research, suggesting interest in bridging basic science and clinical practice, such as moving promising findings from laboratory, preclinical, or early human studies into real-world clinical testing. Finally, NIAAA encourages innovative methods and technologies for AUD treatment and recovery, which can include novel intervention delivery models, digital tools, technology-enabled monitoring, new assessment approaches, or other creative solutions designed to improve access, engagement, adherence, or outcomes.
The opportunity is listed under CFDA number 93.273 and falls within the health funding activity category. Eligible applicants are wide-ranging and include many types of U.S. governmental entities (state, county, city/township, and special district governments), federally recognized Native American tribal governments, and public housing authorities/Indian housing authorities. Academic institutions are eligible, including public and state-controlled institutions of higher education as well as private institutions of higher education. The eligibility list also includes nonprofit organizations with or without 501(c)(3) status (excluding institutions of higher education in those categories), for-profit organizations (other than small businesses), and small businesses, reflecting NIH's broad applicant base for research grants. The NOFO further highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs), as well as faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and certain tribal governments that are not federally recognized. Non-U.S. entities (foreign organizations) are also explicitly included, indicating that international applicants may apply when aligned with NIH policies and program goals.
Key administrative details include an original closing date of 2026-09-07 and an award ceiling listed at $500,000. The grant is categorized as a discretionary NIH award using the grant funding instrument type. Overall, this NOFO is aimed at supporting rigorous clinical trial research that can strengthen the evidence base for treating AUD, improve personalized intervention matching, clarify how and why behavioral treatments work, and develop innovative approaches that better support both treatment response and long-term recovery.Apply for PA 25 163
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.273.
- This funding opportunity was created on 2024-11-27.
- Applicants must submit their applications by 2026-09-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $500,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This is a discretionary grant opportunity from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health (NIH), titled "Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)".
What is the Funding Opportunity Number (NOFO/FOA number)?
The Funding Opportunity Number is PA 25 163.
What grant mechanism does this opportunity use?
This opportunity uses the NIH R01 research project grant mechanism.
Are clinical trials required under this opportunity?
Yes. The opportunity is explicitly labeled "Clinical Trial Required", meaning proposed projects are expected to involve human participants and test interventions or strategies in a controlled, structured way.
What is the overall goal of the program?
The overall goal is to advance research that improves treatment and supports recovery for people with alcohol use disorder (AUD), emphasizing practical, evidence-driven approaches that can improve clinical care and long-term outcomes.
What topics and project types are within scope?
The scope is broad across the AUD treatment and recovery continuum. Supported areas include treatment development and optimization, medications development (pharmacotherapy), behavioral therapies, mechanisms of behavioral change (MOBC), precision medicine approaches, recovery research, translational research, and innovative methods or technologies for treatment and recovery.
Does the NOFO support pharmacotherapy (medications) research?
Yes. The announcement highlights treatment development and optimization, including medications development (pharmacotherapy) and other biological or combined approaches.
Are behavioral therapies and behavioral treatment research encouraged?
Yes. Alongside medication-focused work, the opportunity strongly supports behavioral therapies and research on mechanisms of behavioral change (MOBC).
What does "mechanisms of behavioral change (MOBC)" mean in this context?
MOBC refers to identifying and testing the key processes through which behavioral interventions produce improvements. Examples mentioned include changes in coping skills, craving regulation, decision-making, stress response, social support, or other mediators of change.
What does the NOFO mean by "precision medicine" for AUD?
Precision medicine is described as tailoring treatment based on individual differences, such as biology, clinical presentation, co-occurring conditions, patterns of alcohol use, or other measurable factors that may predict which treatments work best for which people.
Is recovery research included, and what can it cover?
Yes. The NOFO emphasizes recovery research, including topics such as sustaining remission, preventing relapse, improving functioning and quality of life, and understanding recovery trajectories over time.
Does the opportunity encourage translational research?
Yes. The NOFO calls out translational research and signals interest in bridging basic science and clinical practice, including moving promising findings from laboratory, preclinical, or early human studies into real-world clinical testing.
Are innovative methods and technologies allowed or encouraged?
Yes. NIAAA encourages innovative methods and technologies for AUD treatment and recovery. Examples described include novel intervention delivery models, digital tools, technology-enabled monitoring, new assessment approaches, and other solutions designed to improve access, engagement, adherence, or outcomes.
Who is the sponsoring agency?
The sponsoring agency is the National Institute on Alcohol Abuse and Alcoholism (NIAAA), which is part of the National Institutes of Health (NIH).
What is the CFDA number associated with this opportunity?
The CFDA number listed is 93.273.
What funding activity category does this fall under?
The opportunity is listed within the health funding activity category.
What is the funding instrument type?
The funding instrument type is a grant, categorized as a discretionary NIH award.
What is the award ceiling?
The award ceiling is listed as $500,000.
When is the closing date?
The original closing date is listed as 2026-09-07.
Which applicant organizations are eligible?
Eligible applicants are wide-ranging and include U.S. governmental entities (state, county, city/township, and special district governments), federally recognized Native American tribal governments, and public housing authorities/Indian housing authorities. Academic institutions are eligible (public/state-controlled and private institutions of higher education). The eligibility list also includes nonprofit organizations with or without 501(c)(3) status (excluding institutions of higher education in those categories), for-profit organizations (other than small businesses), and small businesses.
Are minority-serving and special-designation institutions included as eligible applicants?
Yes. The NOFO highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs).
Are community-based, faith-based, and regional organizations eligible?
Yes. The NOFO explicitly includes faith-based or community-based organizations and regional organizations among eligible applicants.
Are U.S. territories or possessions eligible to apply?
Yes. The NOFO includes U.S. territories or possessions as eligible applicants.
Are tribal governments that are not federally recognized eligible?
Yes. The eligibility list includes certain tribal governments that are not federally recognized.
Are non-U.S. (foreign) organizations eligible?
Yes. Non-U.S. entities (foreign organizations) are explicitly included as eligible applicants, indicating international applicants may apply when aligned with NIH policies and program goals.
What kind of research outcomes is NIAAA trying to drive through this NOFO?
Based on the description, the NOFO aims to support rigorous clinical trial research that strengthens the evidence base for treating AUD, improves personalized intervention matching, clarifies how and why behavioral treatments work, and develops innovative approaches that support both treatment response and long-term recovery.
Does the NOFO focus only on treatment, or also on longer-term recovery?
It covers both. In addition to treatment development and testing, the NOFO places emphasis on recovery topics such as relapse prevention, sustaining remission, improving functioning and quality of life, and tracking recovery trajectories over time.
Is this opportunity limited to one type of intervention approach?
No. The scope is described as intentionally broad and includes pharmacotherapy, behavioral therapies, biological or combined approaches, translational pathways, and technology-enabled or otherwise innovative models.
Browse more opportunities from the same category: Health
Next opportunity: Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
Previous opportunity: Publishing Historical Records in Collaborative Digital Editions
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 25 163
Applicants also applied for:
Applicants who have applied for this opportunity (PA 25 163) also looked into and applied for these:
| Funding Opportunity |
|---|
| Artificial Intelligence in Pre-clinical Drug Development for AD/ADRD (R01 Clinical Trial Not Allowed) Apply for RFA AG 24 049 Funding Number: RFA AG 24 049 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required) Apply for PAR 25 188 Funding Number: PAR 25 188 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| In Vivo Non-Invasive Optical Imaging Approaches for Biological Systems (UG3/UH3 Clinical Trials Not Allowed Apply for RFA RM 24 012 Funding Number: RFA RM 24 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Required) Apply for PAR 25 216 Funding Number: PAR 25 216 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Not Allowed) Apply for PAR 25 215 Funding Number: PAR 25 215 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required) Apply for PAR 25 271 Funding Number: PAR 25 271 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required) Apply for PAR 25 270 Funding Number: PAR 25 270 Agency: National Institutes of Health Category: Health Funding Amount: $1,050,000 |
| Targeting Cell Surface HIV Envelope for Cell Elimination (R01 Clinical Trial Not Allowed) Apply for PAR 25 300 Funding Number: PAR 25 300 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required) Apply for PAR 25 269 Funding Number: PAR 25 269 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| PEPFAR Community Led Monitoring (CLM)-Zambia Apply for PCLM 2025 Funding Number: PCLM 2025 Agency: U.S. Mission to Zambia Category: Health Funding Amount: $115,000 |
| USAID SUstaining Control of the HIV Epidemic through quality Services, resilient Systems, and Community Outreach (SUCESSO) _ Sofala & Niassa Apply for 72065625RFA00002 Funding Number: 72065625RFA00002 Agency: Mozambique USAID-Maputo Category: Health Funding Amount: $77,500,000 |
| NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed) Apply for PAR 25 251 Funding Number: PAR 25 251 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| USAID Sustaining Control of the HIV Epidemic through quality Services, resilient systems, and Community Outreach (SUCESSO) - Tete & Manica Apply for 72065625RFA00005 Funding Number: 72065625RFA00005 Agency: Mozambique USAID-Maputo Category: Health Funding Amount: $77,500,000 |
| Accelerating Solutions to Improve Access and Quality of Empirically-Supported Practices for Youth Mental Health (R01 Clinical Trial Optional) Apply for PAR 25 310 Funding Number: PAR 25 310 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) Apply for PAR 25 297 Funding Number: PAR 25 297 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required) Apply for PAR 25 026 Funding Number: PAR 25 026 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required) Apply for PAR 25 025 Funding Number: PAR 25 025 Agency: National Institutes of Health Category: Health Funding Amount: $1,515,000 |
| High-Priority Research in Tobacco Regulatory Science (R01 Clinical Trial Optional) Apply for RFA OD 25 001 Funding Number: RFA OD 25 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed) Apply for PAR 25 239 Funding Number: PAR 25 239 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIMH Career Transition Award for Tenure-Track Intramural Investigators (K22 Independent Clinical Trial Not Allowed) Apply for PAR 24 286 Funding Number: PAR 24 286 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 25 163", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.